US pharmaceutical company Moderna Inc (Nasdaq:MRNA) expects to report data from its COVID-19 vaccine trial in children aged two to five years in March 2022, Reuters news agency reported on Thursday.
According to Moderna, if the data is supportive and subject to regulatory consultation, it may then proceed with regulatory filings for children in this age group.
Moderna's mRNA COVID-19 vaccine is already authorised in Europe, the UK, Australia and Canada for adolescents aged 12 to 17 years.
In the United States, the Moderna vaccine is authorised by Food and Drug Administration as primary two-dose regimen and booster dose for adults 18 years and older. The company is yet to get authorisation from the US regulator for use of its vaccine in children.
AstraZeneca and RQ Biotechnology sign licence agreement for monoclonal antibodies against COVID-19
Boheringer Ingelheim introduces TwistPak(R) mixing platform for swine vaccines
Medicago Announces Publication of Covifenz Phase 3 COVID-19 Vaccine Study Results
International Pregistry Study Examines Treatments Used for COVID-19 During Pregnancy
Intravacc BV signs exclusive licensing agreement with Beijing Zhifei Lvzhu Biopharmaceutical
Moderna seeks US authorisation for its COVID-19 vaccine for young children
AstraZeneca's COVID-19 vaccine sales exceed expectations
GSK and SK Bioscience' submit COVID-19 vaccine for approval in South Korea